Management of Clamshell Fractures in Total Hip Arthroplasty: A Rarely Recognized Periprosthetic Injury Pattern

Felix Haussner1, Michael Fuchs1, Moritz Oltmanns1

  • 1Department of Orthopaedic Surgery, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.

PubMed

Insights

Periprosthetic femoral fractures (PPFFs) are a common reason for hip replacement revision. This review focuses on the underrecognized clamshell fracture pattern and its treatment options.

Area of Science:

  • Orthopedic Surgery
  • Biomedical Engineering

Background:

  • Periprosthetic femoral fractures (PPFFs) are the third leading cause for revision total hip arthroplasty (THA).
  • The incidence of PPFFs is rising due to the increasing number of primary hip replacements.
  • Clamshell fractures (CFs) are an underrecognized and controversial PPFF pattern often omitted from classifications.

Purpose of the Study:

  • To provide a comprehensive overview of clamshell fractures as a distinct periprosthetic injury pattern.
  • To outline and discuss treatment options for CFs based on biomechanical considerations.
  • To address the limited current literature and poorly defined standardized therapeutic approaches for CFs.

Main Methods:

  • Literature review focusing on periprosthetic femoral fractures and clamshell fractures.
  • Analysis of biomechanical principles relevant to fracture treatment.
  • Discussion of current therapeutic options and their limitations.

Main Results:

  • Clamshell fractures represent a significant and underestimated pattern of periprosthetic injury.
  • Treatment strategies for CFs are diverse, depending on patient factors and stem stability.
  • Standardized therapeutic approaches for CFs are not well-defined in existing literature.

Conclusions:

  • Clamshell fractures require specific attention within the spectrum of periprosthetic femoral fractures.
  • Further research and standardized guidelines are needed for optimal management of CFs.
  • Biomechanical considerations are crucial for selecting appropriate treatment for CFs.